Product
WXFL10030390
1 clinical trial
1 indication
Indication
Advanced CancerClinical trial
A Phase Ⅰ Study of PI3K/mTOR Dual Inhibitor WXFL10030390 to Evaluate the Safety, Tolerability and Pharmacokinetics in Patients With Advanced Solid Tumors or LymphomaStatus: Completed, Estimated PCD: 2020-07-25